Briefs: Natco Pharma and Panacea Biotec
Drug Approval

Briefs: Natco Pharma and Panacea Biotec

Panacea Biotec has announced the launch of its new range of high-quality pediatric food & nutritional products

  • By IPP Bureau | June 16, 2023

Natco Pharma receives EIR from USFDA for Vizag facility

Natco Pharma Limited has announced the successful closure of inspection and received Establishment Inspection Report (EIR) from the U.S. Food and Drug Administration (USFDA) for its drug formulations manufacturing facility at Visakhapatnam (Vizag), Andhra Pradesh, India, for an inspection conducted during the period from 30th January to 3rd February 2023.

Panacea Biotec launches new range of pediatric food and nutritional products in India

Panacea Biotec Limited, one of India's leading biotechnology company, has announced the launch of its new range of high-quality pediatric food & nutritional products ChilRun, ChilRun Full, ChilRun No Sucrose, ChilRun 7+ in different flavours and sizes in India by its wholly owned subsidiary, Panacea Biotec Pharma Limited.

Upcoming E-conference

Other Related stories

Startup

Digitization